[go: up one dir, main page]

WO2010017500A3 - Anti-pancreatic cancer antibodies - Google Patents

Anti-pancreatic cancer antibodies Download PDF

Info

Publication number
WO2010017500A3
WO2010017500A3 PCT/US2009/053192 US2009053192W WO2010017500A3 WO 2010017500 A3 WO2010017500 A3 WO 2010017500A3 US 2009053192 W US2009053192 W US 2009053192W WO 2010017500 A3 WO2010017500 A3 WO 2010017500A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
pancreatic
pancreatic cancer
bind
pam4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/053192
Other languages
French (fr)
Other versions
WO2010017500A2 (en
Inventor
David M. Goldenberg
Hans J. Hansen
Chien-Hsing Chang
David V. Gold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/343,655 external-priority patent/US7993626B2/en
Priority claimed from US12/418,877 external-priority patent/US7906118B2/en
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Priority to AU2009279503A priority Critical patent/AU2009279503B2/en
Priority to CN200980134258.8A priority patent/CN102137681B/en
Priority to JP2011522288A priority patent/JP5919604B2/en
Priority to CA2731438A priority patent/CA2731438C/en
Priority to EP09805623.7A priority patent/EP2331134A4/en
Publication of WO2010017500A2 publication Critical patent/WO2010017500A2/en
Publication of WO2010017500A3 publication Critical patent/WO2010017500A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G01N33/57525—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The subject antibodies show a number of novel and useful therapeutic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. In preferred embodiments, the antibodies bind to pancreatic cancer mucins. The antibodies and fragments are of use for the detection, diagnosis and/or treatment of cancer, such as pancreatic cancer. The antibodies, such as PAM4 antibodies, bind to a PAM4 antigen that shows unique cell and tissue distributions compared with other known antibodies such as CA19.9, DUPAN2, SPAN1, Nd2, B72.3, and Leaª and Le(y) antibodies that bind to the Lewis antigens.
PCT/US2009/053192 2008-08-08 2009-08-07 Anti-pancreatic cancer antibodies Ceased WO2010017500A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2009279503A AU2009279503B2 (en) 2008-08-08 2009-08-07 Anti-pancreatic cancer antibodies
CN200980134258.8A CN102137681B (en) 2008-08-08 2009-08-07 Anti-pancreatic cancer antibodies
JP2011522288A JP5919604B2 (en) 2008-08-08 2009-08-07 Anti-pancreatic cancer antibody
CA2731438A CA2731438C (en) 2008-08-08 2009-08-07 Anti-pancreatic cancer antibodies
EP09805623.7A EP2331134A4 (en) 2008-08-08 2009-08-07 PANCREATIC ANTI-CANCER ANTIBODIES

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US8746308P 2008-08-08 2008-08-08
US61/087,463 2008-08-08
US12/343,655 US7993626B2 (en) 2007-01-11 2008-12-24 Methods and compositions for F-18 labeling of proteins, peptides and other molecules
US12/343,655 2008-12-24
US14422709P 2009-01-13 2009-01-13
US61/144,227 2009-01-13
US12/418,877 2009-04-06
US12/418,877 US7906118B2 (en) 2005-04-06 2009-04-06 Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology

Publications (2)

Publication Number Publication Date
WO2010017500A2 WO2010017500A2 (en) 2010-02-11
WO2010017500A3 true WO2010017500A3 (en) 2010-04-22

Family

ID=41664221

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/053192 Ceased WO2010017500A2 (en) 2008-08-08 2009-08-07 Anti-pancreatic cancer antibodies

Country Status (6)

Country Link
EP (1) EP2331134A4 (en)
JP (2) JP5919604B2 (en)
CN (1) CN102137681B (en)
AU (1) AU2009279503B2 (en)
CA (1) CA2731438C (en)
WO (1) WO2010017500A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102485753A (en) * 2010-12-03 2012-06-06 上海杰隆生物工程股份有限公司 Human derived heavy chain variable region possessing human vascular endothelial growth factor binding activity

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481041B2 (en) 2005-04-06 2013-07-09 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
WO2011138462A1 (en) * 2010-05-07 2011-11-10 F. Hoffmann-La Roche Ag Diagnostic method for the detection of cells ex vivo
AU2011323354B2 (en) * 2010-11-03 2014-07-31 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy
EP2646055A4 (en) * 2010-12-02 2015-04-08 Immunomedics Inc In vivo copper-free click chemistry for delivery of therapeutic and/or diagnostic agents
SG11201402364WA (en) * 2011-11-15 2014-09-26 Quincy Bioscience Llc Apoaequorin for reducing neuronal injury due to ischemia
KR20230078823A (en) * 2012-12-13 2023-06-02 이뮤노메딕스, 인코오포레이티드 Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
EP2981829A4 (en) * 2013-04-01 2016-10-26 Immunomedics Inc ANTI-MUCIN ANTIBODIES FOR EARLY DETECTION AND TREATMENT OF PANCREATIC CANCER
CN107252485A (en) * 2013-04-03 2017-10-17 Ibc药品公司 For inducing the combination treatment to the immune response of disease
EP3015864A4 (en) * 2013-06-14 2017-01-18 Universidad de Granada Biomarkers for the diagnosis and the response to treatment of pancreatic cancer
KR20150129932A (en) * 2014-05-12 2015-11-23 연세대학교 산학협력단 A kit for pancreatic cancer diagnosis comprising complememt factor b-specific binding antibody
CA2948013A1 (en) * 2014-06-30 2016-01-07 Immunomedics, Inc. Antibodies reactive with an epitope located in the n-terminal region of muc5ac comprising cysteine-rich subdomain 2 (cys2)
KR20160045547A (en) * 2014-10-17 2016-04-27 에스케이텔레콤 주식회사 Composition for diagnosing pancreatic cancer and method for diagnosing pancreatic cancer using the same
CN104974988B (en) * 2015-07-31 2016-08-24 南京麦科林生物医药科技有限公司 Anti-pancreatic cancer monoclonal antibody and application thereof
CN119236123A (en) * 2018-04-05 2025-01-03 融合制药公司 HSP90-targeted conjugates and their preparations
JP7560445B2 (en) * 2018-09-10 2024-10-02 コールド スプリング ハーバー ラボラトリー Methods for Treating Pancreatitis
EP4049684A4 (en) * 2019-10-18 2023-10-25 Nihon Medi-Physics Co., Ltd Ri-labeled humanized antibody
JP2024503995A (en) * 2020-12-16 2024-01-30 アルファ タウ メディカル リミテッド Diffuse alpha emitter radiotherapy with enhanced beta radiation therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050014207A1 (en) * 2002-06-14 2005-01-20 Immunomedics, Inc. Monoclonal antibody hPAM4
US20070044171A1 (en) * 2000-12-14 2007-02-22 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US20080171067A1 (en) * 2007-01-17 2008-07-17 Immunomedics, Inc. Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6357596A (en) * 1986-08-29 1988-03-12 Nisshin Flour Milling Co Ltd Monoclonal antibody, production thereof and diagnosticum for hepatopathy composed of said antibody
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU2006232310B9 (en) * 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070044171A1 (en) * 2000-12-14 2007-02-22 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US20050014207A1 (en) * 2002-06-14 2005-01-20 Immunomedics, Inc. Monoclonal antibody hPAM4
US20080171067A1 (en) * 2007-01-17 2008-07-17 Immunomedics, Inc. Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GOLD ET AL.: "A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma.", CANCER RES, vol. 68, no. 12, 15 June 2008 (2008-06-15), pages 4819 - 4826, XP002541923 *
GOLD ET AL.: "PAM4-Reactive MUC1 Is a Biomarker for Early Pancreatic Adenocarcinoma.", CLIN CANCER RES, vol. 13, no. 24, 15 December 2007 (2007-12-15), pages 7380 - 7387, XP008144324 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102485753A (en) * 2010-12-03 2012-06-06 上海杰隆生物工程股份有限公司 Human derived heavy chain variable region possessing human vascular endothelial growth factor binding activity

Also Published As

Publication number Publication date
JP2011530536A (en) 2011-12-22
JP5919604B2 (en) 2016-05-18
JP2015110618A (en) 2015-06-18
CA2731438A1 (en) 2010-02-11
WO2010017500A2 (en) 2010-02-11
EP2331134A2 (en) 2011-06-15
CA2731438C (en) 2017-07-11
AU2009279503A1 (en) 2010-02-11
CN102137681A (en) 2011-07-27
AU2009279503B2 (en) 2014-05-29
EP2331134A4 (en) 2014-10-15
CN102137681B (en) 2014-12-03

Similar Documents

Publication Publication Date Title
WO2010017500A3 (en) Anti-pancreatic cancer antibodies
WO2012112443A3 (en) Anti-mucin antibodies for early detection and treatment of pancreatic cancer
WO2009120905A3 (en) Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
SG153825A1 (en) Multivalent immunoglobulin-based bioactive assemblies
EA200970130A1 (en) ANTAGONISTIC ANTIBODE FOR CANCER TREATMENT
EP4279140A3 (en) Human antibodies against tissue factor
WO2005054273A3 (en) Humanized antibodies against vascular endothelial growth factor
AU2006226733A8 (en) Antibodies against CD38 for treatment of multiple myeloma
WO2005103081A3 (en) Human monoclonal antibodies against cd20
IL242336A (en) Method of detecting ca6 glycotope and use of a cytotoxic conjugate in the preparation of a medicament for treating cancer in a subject diagnosed with said cancer in accordance with said method
SG10201407757XA (en) Anti-gcc antibody molecules and related compositions and methods
IN2012DN01663A (en)
WO2009061996A3 (en) Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
WO2008036449A3 (en) Chemical antibodies for immunotherapy and imaging
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
WO2007145840A3 (en) Compositions and methods for diagnosing and treating cancer
WO2006099141A3 (en) Anti-mesothelin antibodies
WO2010019702A3 (en) Ddr1-binding agents and methods of use thereof
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
CA2740134C (en) Formulations targeting igfbp7 for diagnosis and therapy of cancer
WO2011091113A3 (en) Detection of early-stage pancreatic adenocarcinoma
GEP20135826B (en) Novel antibodies used to treat cancer
PH12021553289A1 (en) Anti-tissue factor antibody-drug conjugates and related methods
ZA202302392B (en) Antibodies against ilt2 and use thereof
WO2011040973A3 (en) Tnf-immunoconjugates with fibroblast activation protein antibodies and methods and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980134258.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09805623

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009279503

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2731438

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2011522288

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009279503

Country of ref document: AU

Date of ref document: 20090807

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 961/DELNP/2011

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009805623

Country of ref document: EP